Warren Nighan JR - Sep 22, 2021 Form 3 Insider Report for ANGIODYNAMICS INC (ANGO)

Role
SVP Quality and Regulatory
Signature
/s/ Richard C. Rosenzweig, Attorney in Fact
Stock symbol
ANGO
Transactions as of
Sep 22, 2021
Transactions value $
$0
Form type
3
Date filed
12/30/2021, 05:03 PM
Next filing
Jul 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ANGO Common Stock 33.9K Sep 22, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ANGO Non-Qualified Stock Option (right to buy) Sep 22, 2021 Common Stock 50K $15.52 Direct F2
holding ANGO Non-Qualified Stock Option (right to buy) Sep 22, 2021 Common Stock 11.9K $16.55 Direct F3
holding ANGO Non-Qualified Stock Option (right to buy) Sep 22, 2021 Common Stock 15.2K $20.93 Direct F4
holding ANGO Non-Qualified Stock Option (right to buy) Sep 22, 2021 Common Stock 10.8K $21.54 Direct F5
holding ANGO Non-Qualified Stock Option (right to buy) Sep 22, 2021 Common Stock 20.6K $9.92 Direct F6
holding ANGO Non-Qualified Stock Option (right to buy) Sep 22, 2021 Common Stock 10.3K $26.49 Direct F7
holding ANGO Performance Right Sep 22, 2021 Common Stock 4.3K Direct F8
holding ANGO Performance Right Sep 22, 2021 Common Stock 14K Direct F9
holding ANGO Performance Right Sep 22, 2021 Common Stock 7.55K Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares of common stock of AngioDynamics, Inc. ("Common Stock") include (i) 1,195 shares of Common Stock underlying restricted stock units which vest on July 18, 2022, (ii) 1,614 shares of Common Stock underlying restricted stock units which vest in two equal annual installments on each of July 17, 2022 and 2023, (iii) 5,254 shares of Common Stock underlying restricted stock units which vest in three equal annual installments on each of July 14, 2022, 2023 and 2024, and (iv) 3,775 shares of Common Stock underlying restricted stock units which vest in four equal annual installments on each of July 21, 2022, 2023, 2024 and 2025.
F2 These stock options have fully vested and are exercisable.
F3 These stock options have fully vested and are exercisable.
F4 75% of these stock options have fully vested and are exercisable. 25% of these stock options vest on July 18, 2022.
F5 50% of these stock options have fully vested and are exercisable. 50% of these stock options vest in two equal annual installments on each of July 17, 2022 and 2023.
F6 25% of these stock options have fully vested and are exercisable. 75% of these stock options vest in three equal annual installments on each of July 14, 2022, 2023 and 2024.
F7 These stock options vest in four equal annual installments on each of July 21, 2022, 2023, 2024 and 2025.
F8 Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in column 3 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.
F9 Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in column 3 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.
F10 Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in column 3 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

Remarks:

Exhibit List: Exhibit 24.1 - Power of Attorney